genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Cancer
Changing Carcinogenic Cells in the Lungs with Novel Technology
Gastrointestinal Disorders
GI GVHD Link to Microbiome Dysbiosis Addressed by Reducing Intestinal Oxygen
Cancer
Molecular Anchor Creates More Effective CAR T Immunotherapies
Cancer
White House Continues Dedication to “End Cancer as We Know It”
Cancer
Molecular Pathways Used by Metastatic Cancer Cells Uncovered
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Spatial Biology
Spatial Biology Current State of the Art and What’s Coming Next
Spatial Biology
GEN Interview with Joseph M. Beechem, PhD, Chief Scientific Officer of…
Spatial Biology
Choosing the Right Spatial Technology
Spatial Biology
Spatial and NGS Dominate Proceedings at AGBT 2022
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Home
Therapeutics
Enzyme Replacement Therapy
Enzyme Replacement Therapy
Anti-Ulcerants
Antibacterials
Antibiotics
Anticoagulants
Antidiabetics
Antifungals
Antivirals
Autoimmune Disease Drugs
Biologics
Biosimilars
Cardiovascular Drugs
Cellular Therapeutics
Combination Therapies
Dermatologic Drugs
Enzyme Replacement Therapy
Generics
Hormone Replacement Therapy
Immuno-oncology
Immunotherapies
Lipid Regulators
Mental Health Drugs
Oncologics
Orphan Drugs
Pain
Protein Therapeutics
Psychoactive Drugs
Radiopharmaceuticals
Respiratory Drugs
Traditional Chinese Medications
Vaccines
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Enzyme Replacement Therapy
Rubius Therapeutics Closes $120M Financing, Plans Trials Next Year
Enzyme Replacement Therapy
Alexion to Eliminate 7% of Workforce
Enzyme Replacement Therapy
Amicus Cuts Jobs, Overhauls GSK Collab, and Acquires Callidus
Enzyme Replacement Therapy
Lonza to Manufacture Heart Failure Enzyme Replacement Therapy
Enzyme Replacement Therapy
Genzyme Gets FDA, EMA Approvals for Production Plant in Waterford, Ireland
Enzyme Replacement Therapy
Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso
Enzyme Replacement Therapy
EMA Green-Lights Shire’s Manufacturing Site in Lexington, MA, for Gaucher Therapy
Enzyme Replacement Therapy
Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate
Enzyme Replacement Therapy
Oxyrane Raises $26.5M to Take Lead Enzyme Replacement Therapy Through Phase...
Enzyme Replacement Therapy
Enobia Raises $40M to Further Develop Phase II-Stage ERT for Hypophosphatasia
Enzyme Replacement Therapy
Synageva Merges with Trimeris in All-Stock Deal
Enzyme Replacement Therapy
Halozyme and Intrexon to Develop Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
Enzyme Replacement Therapy
Synageva Raises $25M Through Private Placement with Existing Investors
Enzyme Replacement Therapy
Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy
Enzyme Replacement Therapy
GSK Pays Amicus $30M Up Front for Phase III Fabry Disease...
1
2
Page 1 of 2
Scroll Up
Login
Subscribe